Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Adverse drug events

HRT linked with increased stroke risk, conclude Cochrane reviewers

Hormone replacement therapy (HRT), pictured, has little if any benefit in the prevention of cardiovascular disease and causes an increase in the risk of stroke and venous thromboembolic events

Source: Shutterstock.com

Hormone replacement therapy has little if any benefit in the primary or secondary prevention of cardiovascular disease, say researchers

The impact of hormone replacement therapy (HRT) on cardiovascular (CV) risk is unclear. Observational studies have shown a possible protective effect whereas randomised controlled trials (RCTs) have been mixed.

The latest analysis, undertaken by the Cochrane Collaboration (online, 10 March 2015)[1], suggests that HRT has little if any benefit in the primary or secondary prevention of CV disease and causes an increase in the risk of stroke and venous thromboembolic events (VTE).

The review included 19 RCTs, of generally high quality, involving 40,410 postmenopausal women. The relative risks associated with HRT use versus non-use were 1.24 for stroke, 1.92 for any VTE and 1.81 for pulmonary embolism.

“We are confident that the results of our review are close to the true effects,” the authors note. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068148

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.